SXSW 2025
Detecting and Delaying the Onset of Cognitive Decline
Description:
Over 55 million people in the world today are living with dementia. This number is projected to 2x within the next 20 years, unless something changes. This session will explore complementary interventions and technologies that are altering the trajectory of dementia in our society, which is currently a terminal diagnosis. The discussion will focus on new tools for identifying the earliest signs of cognitive decline and the interventions that exist today to slow or reverse the progression of disease. The panelists bring perspectives from pharma, medtech, digital health, and neuromodulation.
Related Media
Other Resources / Information
Takeaways
- Can cognition be objectively screened for early enough such that dementia can be delayed or prevented?
- If one receives a timely diagnosis, what lifestyle and pharma interventions can slow the rate of decline, maintaining more cognitively healthy years?
- How can neuromodulation potentially be used to restore brain function by inducing neuroplasticity within key brain networks related to memory?
Speakers
- Phyllis Ferrell, Chief Impact Officer, StartUp Health
- Ken Mariash, CEO, Sinaptica Therapeutics
- Jen Flexman, COO & Co-Founder, Moneta Health
- Ryan Field, CEO & CTO, Kernel
Organizer
Ryan Field, CEO & CTO, Kernel
SXSW reserves the right to restrict access to or availability of comments related to PanelPicker proposals that it considers objectionable.
Add Comments